INCY
Incyte Corporation NASDAQ$97.14
Pre-mkt
$98.00
+0.89%
Mkt Cap $19.4B
52w Low $57.77
72.2% of range
52w High $112.29
50d MA $95.73
200d MA $93.49
P/E (TTM)
14.7x
EV/EBITDA
9.2x
P/B
3.7x
Debt/Equity
0.0x
ROE
25.5%
P/FCF
14.2x
RSI (14)
—
ATR (14)
—
Beta
0.86
50d MA
$95.73
200d MA
$93.49
Avg Volume
1.7M
About
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor t…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 1.38 | 1.81 | +31.2% | 97.74 | +1.5% | +1.4% | -2.5% | -0.8% | — | — | — | — |
| Feb 10, 2026 | TNS | 1.90 | 1.80 | -5.3% | 100.05 | -1.5% | -1.2% | +0.7% | +1.0% | +1.1% | +2.9% | -8.0% | — |
| Oct 28, 2025 | TNS | 1.66 | 2.26 | +36.1% | 91.65 | -0.2% | -1.6% | +1.0% | +2.0% | +10.8% | +12.3% | +14.0% | — |
| Jul 29, 2025 | TNS | 1.39 | 1.57 | +12.9% | 77.38 | +0.6% | +0.2% | -3.2% | -2.3% | +0.9% | +0.4% | +8.2% | — |
| Apr 29, 2025 | TNS | 1.01 | 1.16 | +14.9% | 60.43 | +0.9% | +3.7% | +2.6% | +3.5% | +2.8% | -1.4% | +9.3% | — |
| Feb 10, 2025 | TNS | 1.57 | 1.43 | -8.9% | 68.30 | -1.1% | -2.9% | +1.1% | +2.5% | +3.1% | +4.3% | -0.8% | — |
| Oct 29, 2024 | TNS | 1.12 | 1.07 | -4.5% | 73.60 | +0.0% | +0.4% | +0.7% | +3.4% | +2.9% | +5.0% | +1.3% | — |
| Jul 30, 2024 | TNS | 0.78 | -1.82 | -333.3% | 67.79 | +0.1% | -4.0% | -5.0% | -4.9% | -8.5% | -9.6% | -2.8% | — |
| Apr 30, 2024 | TNS | 0.84 | 0.64 | -23.8% | 52.05 | -0.3% | +1.7% | +2.0% | +3.3% | +3.9% | +4.5% | +10.1% | — |
| Feb 13, 2024 | TNS | 1.16 | 1.06 | -8.6% | 59.34 | -1.3% | -2.4% | -0.6% | -2.3% | -0.9% | +1.7% | -1.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Stifel | Maintains | Buy → Buy | — | $97.74 | $99.18 | +1.5% | +1.4% | -2.5% | -0.8% | — | — |
| Apr 29 | Oppenheimer | Maintains | Perform → Perform | — | $97.74 | $99.18 | +1.5% | +1.4% | -2.5% | -0.8% | — | — |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $97.69 | $98.75 | +1.1% | -0.6% | -2.4% | +0.1% | -0.8% | -1.5% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.30 | $91.13 | +0.9% | +0.0% | +4.2% | +4.4% | +6.2% | +5.0% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.62 | $91.00 | +0.4% | +1.8% | +1.8% | -0.4% | -0.3% | +3.9% |
| Mar 25 | UBS | Maintains | Neutral → Neutral | — | $90.62 | $91.00 | +0.4% | +1.8% | +1.8% | -0.4% | -0.3% | +3.9% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $92.54 | $92.14 | -0.4% | +0.5% | +1.8% | -0.3% | +0.4% | -1.9% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $95.94 | $95.94 | +0.0% | +1.2% | +0.1% | -1.3% | -4.1% | -3.5% |
| Mar 5 | Evercore ISI | Maintains | In Line → In Line | — | $98.86 | $97.99 | -0.9% | -1.5% | -3.0% | -1.8% | -2.9% | -4.2% |
| Feb 18 | Barclays | Maintains | Overweight → Overweight | — | $101.16 | $100.77 | -0.4% | +1.8% | +0.6% | +0.2% | -0.3% | -0.1% |
Recent Filings
8-K · 8.01
!! High
MacroGenics, Inc. -- 8-K 8.01: Material Event / Announcement
MacroGenics amended its Royalty Purchase Agreement on May 4, 2026, potentially securing additional financing or modifying royalty payment terms to strengthen its financial position.
May 4
8-K
Incyte Genomics Inc -- 8-K Filing
Incyte delivered strong Q1 2026 results with 20% year-over-year net sales growth, demonstrating solid commercial execution and providing positive momentum heading into the remainder of the year.
Apr 28
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Incyte's executive departure signals potential strategic uncertainty, which could concern investors if the departing executive held critical operational or R&D responsibilities affecting pipeline progress or earnings guidance.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Incyte's executive leadership restructuring signals management confidence in executing strategy, though investors should monitor whether these appointments strengthen drug development pipelines or indicate preparation for operational challenges ahead.
Mar 26
8-K · 8.01
!! High
Incyte Genomics Inc -- 8-K 8.01: Material Event / Announcement
Incyte received an FDA Complete Response Letter for Zynyz in lung cancer, delaying the supplemental approval despite positive Phase 3 trial data, requiring additional information before resubmission.
Mar 6
8-K
Incyte Genomics Inc -- 8-K Filing
Incyte reported strong fourth quarter and full-year 2025 results driven by core business growth and pipeline advancement, while providing 2026 financial guidance to investors.
Feb 10
Data updated apr 25, 2026 3:30pm
· Source: massive.com